Loading
BHV-1510 is an experimental chemotherapy-delivering antibody being studied alone and with immunotherapy. Early response findings need confirmation in larger trials.
Biohaven reported an early combination cohort with cemiplimab at the October 10, 2025 cutoff: 23 efficacy-evaluable patients across doses had confirmed ORR 52.2%. A selected 2.5 mg/kg dose group had responses in 3/5 NSCLC, 4/4 endometrial and 1/2 urothelial patients. These very small, uncontrolled populations do not establish superiority over approved ADCs or isolate the ADC contribution from immunotherapy. NCT06384807 registers phase 1/2 testing and identifies PBI-410 and GQ1010 as alternative names.
TROP2-directed antibody-drug conjugate delivering a proprietary TOP1 inhibitor payload. Connects to TROP2.
1.BHV-1510's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BHV-1510" OR ABSTRACT:"BHV-1510" OR TITLE:"PBI-410" OR ABSTRACT:"PBI-410" OR TITLE:"GQ1010" OR ABSTRACT:"GQ1010") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BHV-1510, not a curated reading list.
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/